

Pilar Vizcarra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1702777/pilar-vizcarra-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

338
citations

7
h-index

18
g-index

37
ext. papers

532
ext. citations

4.7
avg, IF

3.54
L-index

#	Paper	IF	Citations
30	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.. <i>Vaccine: X</i> , 2022 , 11, 100165	3.8	1
29	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity.. <i>Frontiers in Microbiology</i> , 2021 , 12, 812729	5.7	1
28	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. <i>HIV Medicine</i> , 2021 , 22, 372-378	2.7	52
27	Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021 , 224, 241-245	7	5
26	SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 916.e1-916.e4	9.5	6
25	IFN- γ cell response and IFN- γ release concordance after in vitro SARS-CoV-2 stimulation. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13636	4.6	2
24	COVID-19 and geographical area of origin. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 632.e1-632.e5	9.5	4
23	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1046-1050	5.1	1
22	T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1341	6.8	7
21	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. <i>Emerging Microbes and Infections</i> , 2021 , 10, 493-496	18.9	8
20	Carbapenemase-producing infections in COVID-19 patients. <i>Infectious Diseases</i> , 2021 , 1-10	3.1	5
19	Progression Risk in People with HIV and COVID-19: Predictive Performance of Current Risk Scores. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 613-619	1.6	
18	[Prevalence of low bone mass in individuals with HIV infection]. <i>Medicina Clínica</i> , 2021 , 157, 234-237	1	
17	Prevalence of low bone mass in individuals with HIV infection. <i>Medicina Clínica (English Edition)</i> , 2021 , 157, 234-237	0.3	
16	Expansion of CD56CD16 NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients.. <i>Viruses</i> , 2021 , 14,	6.2	2
15	Implementation of a lung cancer screening initiative in HIV-infected subjects. <i>PLoS ONE</i> , 2021 , 16, e0260069	3.7	0
14	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. <i>Lancet HIV</i> , 2020 , 7, e554-e564	7.8	172

13	Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. <i>International Journal of STD and AIDS</i> , 2020 , 31, 467-473	1.4	4
12	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1955-1960	5.1	2
11	Weight gain in people living with HIV switched to dual therapy: changes in body fat mass. <i>Aids</i> , 2020 , 34, 155-157	3.5	11
10	Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy. <i>Infectious Diseases</i> , 2020 , 52, 202-206 ^{3.1}		4
9	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020 , 222, S8-S19	7	4
8	Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV. <i>HIV Research and Clinical Practice</i> , 2020 , 21, 63-71	1.7	
7	Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients. <i>Antiviral Therapy</i> , 2019 , 24, 467-471	1.6	10
6	Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. <i>HIV Research and Clinical Practice</i> , 2019 , 20, 64-72	1.7	9
5	CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment. <i>International Journal of STD and AIDS</i> , 2019 , 30, 656-662	1.4	4
4	Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. <i>HIV Medicine</i> , 2019 , 20, 648-656	2.7	6
3	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. <i>CJC Open</i> , 2019 , 1, 245-255 ²		2
2	Symtuza in clinical practice. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36 Suppl 2, 31-36	0.9	2
1	COVID-19 in HIV-Infected Individuals: Preliminary Results of a Prospective Cohort. <i>SSRN Electronic Journal</i> ,	1	11